Perfil
John Hayslip currently works at Verastem, Inc., as Chief Medical Officer from 2024.
Dr. Hayslip also formerly worked at The Markey Cancer Center Foundation, as Director-Clinical Research & Data Management, Nektar Therapeutics, as Vice President-Clinical Development, and I-Mab, as Chief Medical Officer from 2022 to 2024.
Dr. Hayslip received his graduate degree from The Medical University of South Carolina and doctorate degree from Northeast Ohio Medical University.
Cargos activos de John Hayslip
| Empresas | Cargo | Inicio |
|---|---|---|
| VERASTEM, INC. | Director Técnico/Científico/I+D | 18/04/2024 |
Antiguos cargos conocidos de John Hayslip.
| Empresas | Cargo | Fin |
|---|---|---|
| NOVABRIDGE BIOSCIENCES | Director Técnico/Científico/I+D | 15/04/2024 |
The Markey Cancer Center Foundation | Corporate Officer/Principal | - |
| NEKTAR THERAPEUTICS | Director Técnico/Científico/I+D | - |
Formación de John Hayslip.
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas privadas | 6 |
|---|---|
Nektar Therapeutics
Nektar Therapeutics Pharmaceuticals: MajorHealth Technology Discovers and develops medicines in areas of high unmet medical need | Health Technology |
Medical University of South Carolina
Medical University of South Carolina Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
The Markey Cancer Center Foundation | |
Verastem, Inc.
Verastem, Inc. BiotechnologyHealth Technology Discovers and develops drugs | Health Technology |
Northeast Ohio Medical University
Northeast Ohio Medical University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
I-Mab
I-Mab Pharmaceuticals: MajorHealth Technology Develops and manufactures medicines for cancer and autoimmune diseases | Health Technology |
- Bolsa de valores
- Insiders
- John Hayslip
















